Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER

AIMS: Because an increased risk of amputation with canagliflozin was reported in the CANVAS trials, there has been a concern about the safety of sodium–glucose cotransporter 2 inhibitors in patients with peripheral artery disease (PAD) who are at higher risk of amputation. METHODS AND RESULTS: A pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Butt, Jawad H, Kondo, Toru, Yang, Mingming, Jhund, Pardeep S, Docherty, Kieran F, Vaduganathan, Muthiah, Claggett, Brian L, Hernandez, Adrian F, Lam, Carolyn S P, Inzucchi, Silvio E, Martinez, Felipe A, de Boer, Rudolf A, Kosiborod, Mikhail N, Desai, Akshay S, Køber, Lars, Ponikowski, Piotr, Sabatine, Marc S, Shah, Sanjiv J, Zaozerska, Natalia, Wilderäng, Ulrica, Bengtsson, Olof, Solomon, Scott D, McMurray, John J V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Fast Track Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10290876/
https://www.ncbi.nlm.nih.gov/pubmed/37220172
http://dx.doi.org/10.1093/eurheartj/ehad276

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10290876/
https://www.ncbi.nlm.nih.gov/pubmed/37220172
http://dx.doi.org/10.1093/eurheartj/ehad276

Ejemplares similares